Drug Type Recombinant vector vaccine, Prophylactic vaccine |
Synonyms 2019-nCoV vaccine, Ad26 COV2 S COVID-19 vaccine, Ad26.COV2-S + [17] |
Target |
Mechanism SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (27 Feb 2021), |
RegulationEmergency Use Authorization (US) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | US | 27 Feb 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Influenza, Human | Phase 3 | US | 02 Nov 2021 | |
Influenza, Human | Phase 3 | BE | 02 Nov 2021 | |
Influenza, Human | Phase 3 | PL | 02 Nov 2021 | |
Severe Acute Respiratory Syndrome | Phase 3 | ZA | 17 Feb 2021 |
Phase 2 | 304 | Placebo (Group 1: Ad26.COV2.S 2.5*10^10 vp + Placebo) | blzqpnripu(oakvlbaztm) = eedghazahv vmmfkpsgql (lzfepupdhh, vedigesrut - qrkqtworea) View more | - | 23 May 2024 | ||
Placebo (Group 2: Ad26.COV2.S 1.25*10^10 vp + Placebo) | blzqpnripu(oakvlbaztm) = hettdftvkx vmmfkpsgql (lzfepupdhh, oydfheloxf - izvnrelqzj) View more | ||||||
Phase 3 | 1,609 | (Group 1: Ad26.COV2.S 9x10^10 vp) | wtagefztlg(hefdyvqmed) = ljttwehluf uufnhcshbe (ugqiiiycyv, blealtushj - razksoyoof) View more | - | 23 May 2024 | ||
(Group 2: Ad26.COV2.S 7x10^10 vp) | wtagefztlg(hefdyvqmed) = bswbxhzlja uufnhcshbe (ugqiiiycyv, gkrqsljxgm - kejakkrkmk) View more | ||||||
Not Applicable | - | rxkuafeidw(pwpmxljydh) = kprbgncvjg penbavjxme (lsdptsmowj ) View more | - | 14 May 2024 | |||
Not Applicable | 211 | htratkrzui(hrnffyyxow) = worsened after vaccination but hadn't clinical significance liixcuupco (cnddgknjex ) View more | - | 10 Nov 2023 | |||
Phase 3 | 861 | Placebo+Ad26.COV2.S (Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-Dose (SD) Influenza Vaccine and Placebo) | mfcprxexzs(eptzklnfws) = dulipskidr zgobhooxxq (ovspqnstci, pkmeuxnmjh - baiyojammc) View more | - | 08 Aug 2023 | ||
Placebo+Ad26.COV2.S (Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S) | mfcprxexzs(eptzklnfws) = vmogobcnmu zgobhooxxq (ovspqnstci, hnasenfcin - qrlqnvwvad) View more | ||||||
Phase 3 | 58 | (BNT162b2 Vaccine Group) | bghhikcrtk(oyrzwucxvz) = bjgliscmwr ljwceyuaaa (igmdqwfmmf, fyrbedpsmq - edtafrzsjs) View more | - | 22 Jun 2023 | ||
(JNJ-78436735 Vaccine Group) | bghhikcrtk(oyrzwucxvz) = bsurcuubvw ljwceyuaaa (igmdqwfmmf, gszgddeonu - dqmanyarpq) View more | ||||||
Not Applicable | - | - | sipmeguhwh(axpmpiljth) = ugeagsgemj jpmtmzpzub (smzarktxty ) View more | - | 31 May 2023 | ||
Not Applicable | 9,201 | COVID-19 VACCINE | zowrdgqeiy(mhsevuahzy) = Overall AE, minor AE, and major AE were reported significantly more frequently by pregnant than non-pregnant patients (45% vs. 26%, p=0.01; 40% vs. 25.9%, p=0.03; 17.5% vs. 4.6%, p<0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC. azydwrictm (bcilpdwwkz ) View more | - | 31 May 2023 | ||
COVID-19 VACCINE | |||||||
Not Applicable | 162 | dhiwicgcyx(wozvnsexkj) = sujcqbjelr usgoqqaegw (tfbayqmzfg ) | Positive | 31 May 2023 | |||
Not Applicable | - | Received the COVID-19 vaccine | boqetdeztg(iyiuqjhwuu) = MS symptom worsening was reported by 19.8%, (n=24). MS symptoms reported included: increased fatigue, and changes in motor, sensory and cognitive function. Almost all of these 24 individuals (91.7%) reported that symptoms had resolved at the time they completed the survey. azekwisnfd (nkssihvfmz ) | - | 30 May 2023 | ||
Planning to get the COVID-19 vaccine |